Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

BACKGROUND: Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between non-small cell lung cancer (NSCLC) patients with varied response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhen, Ding, Zhengping, Yuan, Jie, Shen, Shengping, Jian, Hong, Tan, Qiang, Yang, Yunhai, Chen, Zhiwei, Luo, Qingquan, Cheng, Xinghua, Yu, Yongfeng, Niu, Xiaomin, Qian, Liqiang, Chen, Xiaoke, Gu, Linping, Liu, Ruijun, Ma, Shenglin, Huang, Jia, Chen, Tianxiang, Li, Ziming, Ji, Wenxiang, Song, Liwei, Shen, Lan, Jiang, Long, Yu, Zicheng, Zhang, Chao, Tai, Zaixian, Wang, Changxi, Chen, Rongrong, Carbone, David P., Xia, Xuefeng, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118717/
https://www.ncbi.nlm.nih.gov/pubmed/35585646
http://dx.doi.org/10.1186/s13045-022-01283-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118717/
https://www.ncbi.nlm.nih.gov/pubmed/35585646
http://dx.doi.org/10.1186/s13045-022-01283-7

Ejemplares similares